Please use this identifier to cite or link to this item:
|Title:||Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas|
|Authors:||G. William Letson|
Juan Jose Amador
Harold S. Margolis
International Vaccine Institute, Seoul
Ministry of Health Sri Lanka
Program for Appropriate Technology in Health (PATH)
University of Maryland School of Medicine
|Keywords:||Immunology and Microbiology;Pharmacology, Toxicology and Pharmaceutics|
|Citation:||Human Vaccines. Vol.6, No.10 (2010), 802-809|
|Abstract:||In this review, we consider the issues impacting conduct and design of dengue vaccine trials with reference to the recently published World Health Organization "Guidelines for Conduct of Clinical Trials of Dengue Vaccines in Endemic Areas." We discuss logistic, scientific and ethical challenges concerning evaluation and introduction of dengue vaccines; these range from randomized trials that establish "proof of concept" of vaccine efficacy, to post-"proof of concept" trials, particularly demonstration projects likely to be required for licensure or for the introduction of an already licensed vaccine into public use. We clarify and define the meaning of "proof of concept" in the clinical trial context and the meaning of terms "phase 2b", "phase 3b" and "demonstration project", which are commonly used but have not been defined well in the clinical literature. © 2010 Landes Bioscience.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.